Method, system, and computer program product for tracking of blood glucose variability in diabetes

Patent metadata

Field	Value
Publication number	US-9317657-B2
Application number	US-200913131467-A
Country	US
Kind code	B2
Filing date	Nov 24, 2009
Priority date	Nov 26, 2008
Publication date	Apr 19, 2016
Grant date	Apr 19, 2016

Abstract

An embodiment may be in the field of glycemic analysis and control. More specifically, an embodiment or approach may provide a novel method, system, and computer program for the visual and quantitative tracking of blood glucose variability in diabetes from self-monitoring blood glucose (SMBG) data and/or continuous glucose monitoring (CGM) data. More particularly, an embodiment or aspects thereof may use glucose measurements obtained from self-monitoring data and/or CGM data of an individual or a group of individuals to track and analyze blood glucose variability.

First claim

What is claimed is:

1. A system for visually tracking blood glucose variability in diabetes in a subject, said system comprising:
an acquisition module acquiring a plurality of blood glucose data of the subject over a predefined period of time;
a processor programmed to
compute blood glucose variability of the subject over said predefined period of time using said blood glucose data; and
plot the computed blood glucose variability on an output display in the form of data points on a graph having a coordinate system representing hypoglycemic risk along one axis of said graph and hyperglycemic risk along another axis of said graph;

wherein the location of a data point in said coordinate system of said graph represents a variable degree of control of blood glucose levels of said subject; and
wherein said tracking provides an area of optimal glucose control in said graph, and provides areas in said graph indicating risk for hyperglycemia and hypoglycemia.

2. The system of claim 1 , wherein said graph comprises:
a first axis representing the risk for hypoglycemia; and
a second axis representing the risk for hyperglycemia.

3. The system of claim 1 , wherein said graph comprises:
a first axis representing the Low Blood Glucose Index (LBGI); and
a second axis representing the High Blood Glucose Index (HBGI).

4. The system of claim 1 , wherein said graph comprises:
a first axis representing the inverse-coded lower percentile; and
a second axis representing the upper percentile.

5. The system claim 1 , wherein said graph comprises at least one of:
a first zone representing the optimal control of glucose variability;
a second zone representing moderate deviations into hypoglycemia, but good control of hyperglycemia;
a third zone representing moderate deviations into hyperglycemia, but good control of hypoglycemia;
a fourth zone representing moderate deviations towards both hypoglycemia and hyperglycemia;
a fifth zone representing over-correction of hyperglycemia;
a sixth zone representing over-correction of hypoglycemia;
a seventh zone representing failure to deal with hypoglycemia;
an eighth zone representing failure to deal with hyperglycemia; and
a ninth zone representing an erroneous control.

6. The system of claim 2 , wherein said first axis comprises about the inverse-coded 2.5% of a distribution of said blood glucose data and the second axis comprises about the 97.5% of a distribution of said blood glucose data.

7. The system of claim 2 , wherein said first axis comprises about the 97.5% of a distribution of said blood glucose data and the second axis comprises about the inverse-coded 2.5% of a distribution of said blood glucose data.

8. The system of claim 5 , wherein said graph comprises:
said first zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about 110-200 mg/dl;
said second zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about 110-200 mg/dl;
said third zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about 200-400 mg/dl;
said fourth zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about 200-400 mg/dl;
said fifth zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about 110-200 mg/dl;
said sixth zone further comprises said first axis ranging from about 110-80 mg/dl and said second axis ranging from about greater than 400 mg/dl;
said seventh zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about 200-400 mg/dl;
said eighth zone further comprises said first axis ranging from about 80-50 mg/dl and said second axis ranging from about greater than 400 mg/dl; and
said ninth zone further comprises said first axis ranging from about less than 50 mg/dl and said second axis ranging from about greater than 400 mg/d1.

9. The system of claim 4 , wherein said first axis comprises about the inverse-coded 25% and the second axis comprises about the 75% of said blood glucose data.

10. The system of claim 4 , wherein said second axis comprises about the inverse-coded 25% and the first axis comprises about the 75% of said blood glucose data.

11. The system of claim 5 , wherein:
said first zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about 110-180 mg/dl;
said second zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about 110-180 mg/dl;
said third zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about 180-250 mg/dl;
said fourth zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about 180-250 mg/dl;
said fifth zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about 110-180 mg/dl;
said sixth zone further comprises said first axis ranging from about 110-90 mg/dl and said second axis ranging from about greater than 250 mg/dl;
said seventh zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about 180-250 mg/dl;
said eighth zone further comprises said first axis ranging from about 90-70 mg/dl and said second axis ranging from about greater than 250 mg/dl; and
said ninth zone further comprises said first axis ranging from about less than 70 mg/dl and said second axis ranging from about greater than 250 mg/d1.

12. The system of claim 3 , wherein said first axis comprises a Low Blood Glucose Index (LBGI) of said blood glucose data.

13. The system of claim 12 , wherein said Low Blood Glucose Index (LBGI) is provided by:

LBGI
k
t

=

1

n
k
t

⁢

∑

s
=
1

n
k
t

⁢

⁢

rl
⁡

(

x
ks
t

)

where k is the subject and t is the time period.

14. The system of claim 3 , wherein said second axis comprises a High Blood Glucose Index (HBGI) of said blood glucose data.

15. The system of claim 14 , wherein said High Blood Glucose Index (HBGI) is provided by:

HBGI
k
t

=

1

n

Assignees

• Breton Marc D
• Kovatchev Boris P
• Univ Virginia Patent Found

Inventors

• Breton Marc D
• Kovatchev Boris P

Classifications

• G16H50/20

  for computer-aided diagnosis, e.g. based on medical expert systems · CPC title

• A61B5/14532

  for measuring glucose, e.g. by tissue impedance measurement · CPC title

• A61B5/0002

  Remote monitoring of patients using telemetry, e.g. transmission of vital signals via a communication network (endoradiosondes A61B5/07) · CPC title

• G16H10/20

  for electronic clinical trials or questionnaires · CPC title

• G16H40/63 Primary

  for local operation · CPC title